Federal regulators have asked Novavax (NVAX) to conduct another randomized clinical trial of its Covid-19 vaccine following earlier delays in approval, Liz Essley Whyte of The Wall Street Journal reported, citing people familiar with the matter. This request reportedly could be so costly it threatens the company’s ability to comply. The company was asked by the FDA to show its vaccine is effective with another randomized study after appointees under Health Secretary Robert F. Kennedy Jr. intervened, the people said.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVAX:
- Novavax asked by FDA to complete additional COVID trial, WSJ says
- Novavax down 10% after WSJ report on FDA request for additional vaccine trial
- Novavax has improved clarity on path forward for Nuvaxovid, says BofA
- Unusually active option classes on open April 23rd
- Novavax’s Biologics License Application Nears Approval
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue